Research Papers:

EWS-FLI1 and RNA helicase A interaction inhibitor YK-4-279 inhibits growth of neuroblastoma

Wenjing Sun, Yesenia Rojas, Hao Wang, Yang Yu, Yongfeng Wang, Zhenghu Chen, Kimal Rajapakshe, Xin Xu, Wei Huang, Saurabh Agarwal, Roma H. Patel, Sarah Woodfield, Yanling Zhao, Jingling Jin, Hong Zhang, Angela Major, M. John Hicks, Jason M. Shohet, Sanjeev A. Vasudevan, Cristian Coarfa, Jianhua Yang and Jed G. Nuchtern _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:94780-94792. https://doi.org/10.18632/oncotarget.21933

Metrics: PDF 2298 views  |   HTML 2620 views  |   ?  


Wenjing Sun1,5, Yesenia Rojas1, Hao Wang2,6, Yang Yu1, Yongfeng Wang3, Zhenghu Chen3, Kimal Rajapakshe4, Xin Xu3, Wei Huang3, Saurabh Agarwal3, Roma H. Patel1, Sarah Woodfield1, Yanling Zhao3, Jingling Jin1, Hong Zhang2, Angela Major7, M. John Hicks7, Jason M. Shohet3, Sanjeev A. Vasudevan1, Cristian Coarfa4, Jianhua Yang3 and Jed G. Nuchtern1

1Pediatric Surgery Division, Michael E. Debakey Department of Surgery, Texas Children’s Hospital, Baylor College of Medicine, Houston, TX 77030, USA

2Department of Pathology, MD Anderson Cancer Center, Houston, TX 77030, USA

3Department of Pediatrics, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA

4Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX 77030, USA

5Laboratory of Medical Genetics, Harbin Medical University, Harbin, Heilongjiang 150081, China

6Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, China

7Department of Pathology, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA

Correspondence to:

Jed G. Nuchtern, email: [email protected]

Keywords: neuroblastoma; YK-4-279; chemotherapy; doxorubicin; EWSR1

Abbreviations: NB, neuroblastoma; RHA, RNA helicase A; Dox, doxorubicin

Received: July 12, 2017    Accepted: August 21, 2017    Published: October 19, 2017


Treatment failure in high risk neuroblastoma (NB) is largely due to the development of chemotherapy resistance. We analyzed the gene expression changes associated with exposure to chemotherapy in six high risk NB tumors with the aid of the Connectivity Map bioinformatics platform. Ten therapeutic agents were predicted to have a high probability of reversing the transcriptome changes associated with neoadjuvant chemotherapy treatment. Among these agents, initial screening showed the EWS-FLI1 and RNA helicase A interaction inhibitor YK-4-279, had obvious cytotoxic effects on NB cell lines. Using a panel of NB cell lines, including MYCN nonamplified (SK-N-AS, SH-SY5Y, and CHLA-255), and MYCN amplified (NB-19, NGP, and IMR-32) cell lines, we found that YK-4-279 had cytotoxic effects on all lines tested. In addition, YK-4-279 also inhibited cell proliferation and anchorage-independent growth and induced cell apoptosis of these cells. YK-4-279 enhanced the cytotoxic effect of doxorubicin (Dox). Moreover, YK-4-279 was able to overcome the established chemoresistance of LA-N-6 NB cells. In an orthotopic xenograft NB mouse model, YK-4-279 inhibited NB tumor growth and induced apoptosis in tumor cells through PARP and Caspase 3 cleavage in vivo. While EWS-FLI1 fusion protein is not frequently found in NB, using the R2 public database of neuroblastoma outcome and gene expression, we found that high expression of EWSR1 was associated with poor patient outcome. Knockdown of EWSR1 inhibited the oncogenic potential of neuroblastoma cell lines. Taken together, our results indicate that YK-4-279 might be a promising agent for treatment of NB that merits further exploration.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21933